Loading page
Loading page
Loading substance route
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Moderately addictive with a high potential for abuse and capable of causing psychological dependence among certain users. Compulsive redosing is reported, and cravings may develop with chronic use.
Withdrawal effects may occur if a person suddenly stops usage after developing addiction, though specific physical withdrawal symptoms are not well-documented. The emphasis in available literature is on psychological rather than physical dependence.
The exact toxic dosage is unknown due to the very limited history of human usage. No lethal dose data has been established in any scientific context.
Psychosis is listed as a potential after effect during the comedown period. Anxiety, paranoia, and delusions typically occur with overly high doses or after redosing and staying awake for extended periods, following the pattern typical of stimulant use.
2-FEA emerged as a novel psychoactive substance distributed through online research chemical vendors. Limited formal documentation exists regarding its precise origins, initial synthesis, or the circumstances of its introduction to the recreational drug market.…
Considered a Schedule I controlled substance as an analogue of amphetamine under Canadian drug scheduling laws.
Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since November 26, 2016. Production and import with intent to market, administration to others, and trading are punishable offenses. Possession is prohibited but not subject to criminal penalties.
Classified as a Schedule 3 controlled substance due to its structural relationship to amphetamine under New Zealand's analogue provisions.
Controlled as a Class A substance under the amphetamine analogue clause of the Misuse of Drugs Act 1971. Class A classification carries the most severe penalties under UK drug law.
As of December 2024, 2-FEA is not explicitly scheduled under French drug control legislation. Possession is technically legal, though the substance exists in a regulatory gray area.
Currently unscheduled and legal to possess. However, 2-FEA falls within a substance group that may be prohibited under recently passed legislation targeting new psychoactive substances.
Regulated as a controlled substance under Verzeichnis E point 130 as a defined derivative of α-methylphenethylamine. Exemptions exist for legitimate scientific or industrial applications.
Not a federally controlled substance as of 2011. However, prosecution may be possible under the Federal Analogue Act when sold or possessed with intent for human consumption, as it is structurally related to scheduled amphetamines.
13 sources cited